Cetuximab Enhances the Anti-proliferative Effect of Trastuzumab in ERBB2 Over-expressing Breast Cancer Cells – Preliminary Study
Authors: Überall I., Křížová K., Steigerová J.
Authors - sphere of activity: 1 Institute of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic; 2 Institute of Molecular and Translational Medicine (IMTM), Faculty of Medicine and Dentristry, Palacky University, Olomouc
Article: Klin Onkol 2011; 24(5): 356-360
Category: Original Articles
Number of articles displayed: 155x
The tyrosine kinase receptor comprises a subclass of cell surface growth factor receptors. Inhibition of certain members of the Epidermal Growth Factor Receptor (EGFR) family is an effective treatment approach in some cancers. The anti-tumor effects are greater when this approach is combined with inhibition of the ERBB2 receptors. These studies provide novel experimental data demonstrating a significant augmentation of the anti-proliferative effects of monoclonal antibodies (cetuximab and trastuzumab) on human breast carcinoma cell lines with different level of ERBB receptor expression.
Materials and Methods:
Three breast cancer cell lines, MCF-7, BT-474, and SK-BR-3 were used. These are characterised by different levels of EGFR and/or other ERBB family members. Inhibition of cell growth in response to cetuximab, trastuzumab or their combination was assessed by MTT assay.
The breast cancer cell lines differed in their sensitivity to TZ, CTX and their combination. The SK-BR-3 cancer cell line was sensitive to TZ. On the other hand, CTX had no effect on BT-474 or on SK-BR-3 that expressed low levels of EGFR and high levels of ERBB2.
Our new experimental data show that the combination of anti-EGF receptor and anti-ERBB2 mAb may inhibit cancer cells expressing both EGF and ERBB2 receptors.
ERBB receptors – dual inhibition – trastuzumab – cetuximab – breast cancer
The full wording of this article is available only to registered users. Plese register and you can read this article immediately.
If you are a subscriber, log in and enter the subscriber code from your magazine cover.
If you are not a subscriber, log in for unlimited access to older editions.
Tento článek si můžete přečíst pokud si aktivujete Premium účet.
- Cancer as a Metabolic Disease and Diabetes as a Cancer Risk? | views: 45
- The Role of Platelets in Tumour Growth | views: 21
- p63 – an Important Player in Epidermal and Tumour Development | views: 14
- PThe Regulation of p53 Synthesis | views: 12
- Protein Quality Control and Cancerogenesis | views: 10
- Detection of Cancer Stem Cell Markers in Sarcomas | views: 9
- RECAMO – ...through Cancer Research towards Applied Molecular Oncology; Where, Why and How | views: 7
- NKT-like Cells are Expanded in Solid Tumour Patients | views: 6
- The Many Roles of Molecular Chaperones and Co-chaperones in Tumour Biology | views: 6
- Circulating Levels of B-cell Activating Factor in Paediatric Patients with Malignancy With or without Cancer-Related Cachexia | views: 4